Why Attend
Animal Health Innovation Asia is a premier B2B conference showcasing emerging Animal Health and Nutrition companies, from China and across Asia-Pacific, that are activity seeking financial investment or strategic partnership conversations with large corporate firms.
Our plenary sessions provide guidance on veterinary market trends and animal health industry dynamics in China & A-PAC, insight on how emerging companies are using new innovations to prevent disease and market analysis on the M&A activity across the animal health and nutrition markets in Asia.
Testimonials
"This is a unique event for our animal health industry. It brings local and international players together, and provides an excellent platform to build business partnerships.”
Tony Zilong Tan, Z-Link Biotech Co. Ltd.
“This meeting is a very exciting one – it’s a platform to meet everyone from Chinese animal health and International animal health companies, and to introduce them to one-another. This way you save time and it gives you more chance to keep ahead of the innovations.”
Tingwu Xue, China Animal Husbandry Group (CAHG)
“I think this is a great meeting for companies to come together and find out what the common challenges are and how they can work together. I’m really impressed!"
Jishu Shi, U.S.-China Centre for Animal Health
"Everybody’s here, you can have many meetings in one spot, learn how to work together, increase your network and search for ideas.”
Joachim Hasenmaier, Boehringer-Ingelheim
Highlights from the Series
Innovation Showcase
Our Selection Committee will select twelve Emerging/ Start-up companies from the list of applications to present on-site to the audience of strategic partners from APAC, China and around the world. These presentations will showcase the innovation and opportunity that the emerging companies bring to their various markets.
Submissions will be accepted from companies in the following categories: Nutrition and Health for Livestock or Companion Animals. They should be early to mid-stage companies that are actively looking for financial investment or strategic partnerships, and can range from pre-revenue companies all the way up to larger entities that have annual revenues of up to $10 million USD.
Thank you to everyone that entered!
We're excited to announce the Finalists. Results announced in the Resources section below (click here to be redirected)
Please note: All companies that are selected to present as part of the Showcase will receive a 2nd ticket free of charge for a co-presenter to attend the event.
University Pavilion
Brand new for 2018 is the University Pavilion open networking and poster session.
The top veterinary Universities in Asia Pacific will present their facilities, research and technologies for potential partnering opportunities all day on October 24 & 25.
If you're an academic institution don't miss out on showcasing your research - email Calan for more information: [email protected]
Who You Will Meet
Attendees will represent the following key stakeholder groups in the Animal Health market
- Heads of Business Development, Animal Health, R&D from Multinational Pharmaceutical Companies
- CEOs, CSOs and Heads of Business Development from Emerging Animal Health Companies
- CEOs, Heads of Business Development, Product Discovery and Marketing from Incubators/ Accelerators, Contract Research Orgs, Consultants, Lawyers and other Service Providers
…all of the above with an interest in Livestock, Aquaculture and the Companion Animal markets
Attendees expected from the following key stakeholder groups and organizations
New for 2018
Alongside the already popular Animal Health conference track, this year's event brings you:
Nutrition
- Dedicated animal nutrition track covering: Medicated feed additives, oral vaccines and the animal microbiome; The innovation trends impacting the gut health of companion animals, aquaculture and livestock; The unique regulatory requirements for feed additives in China.
- An Innovation Showcase highlighting the four most exciting partnering and investment opportunities for animal nutrition in China
Academia
- University Pavilion showcasing research from the top veterinary universities in China and Asia- Pacific
- Pre-schedule private meetings to facilitate business-to-academia partnership discussions
- Roundtable discussion on partnering strategies between business and academia
Benefits of Attending
- Identify your next stategic partner in animal health and nutrition.
- Collaborate and make deals with senior-level animal health executives and financial investors.
- Discover the latest advancements in innovation and R&D.
- Gain the investment or M&A interest your business needs to succeed in the marketplace.
The Agenda
You can download our latest agenda here.
Simply fill in this form and we'll send you a PDF version immediately. We need some information to know where to send the file and how to address our email to you.
New for 2018 the event has expanded to cover three key areas: Health, Nutrition and Academia. Sessions include:
- INNOVATION: Health and nutrition start-ups from China and A-PAC pitch their novel technologies, looking for partnership opportunities in 3 Showcases
- HEALTH TRACK: Back for its 3rd year, covering animal health M&A, product regulation, drivers of the Chinese pet industry and implications of emerging diseases in A-PAC
- NUTRITION TRACK: Dedicated animal nutrition track covering oral vaccines, innovation in gut health, and regulatory requirements for feed additives in China
- ACADEMIC TRACK: A university pavilion showcasing research from the top 15 veterinary universities in China and A-PAC
Download the agenda to learn more...
Download the 2018 Agenda
NEW FOR 2018: WORKSHOPS
WORKSHOP 1: Preventive Health and Wellbeing in Swine
This is an exclusive opportunity for innovative companies, Key Opinion Leaders and researchers in China and the APAC region to partner with leading global animal health company, Elanco.
Elanco Animal Health are world leaders in prevention through their portfolio of products to prevent and treat parasites and infectious diseases in swine and have one of the highest levels of investment in the creation of future solutions in these areas.
Attendees to this workshop should be experts in the areas of prevention and wellbeing in swine and should contribute to a state-of-the-art debate as to actionable solutions to advance these areas. They can expect to work together with Elanco Animal Health senior executives in the early assessment of high potential opportunities and action plans around collaboration and strategic partnerships.
Attendance for maximum 30 APAC start-up companies or academic researchers only. Individuals must apply for a complimentary pass online.
----------
WORKSHOP 2: Partnering to Transform an Idea into a Final Product: What a leading Animal Health company can bring to a Start-up
- A vast regulatory world outside of China.... with rules, traditions, complexities
- Great discoveries need suitable marketing formulations
- A misled IP review, a potential nightmare even for the best inventions
- Quality and Good Practices... Expanding into other territories for global sales
Attendance for maximum 30 APAC start-up companies or academic researchers only. Individuals must apply for a complimentary pass online.
Applications for both workshops are now closed
Speakers
Dr. Cai XuePeng
Dr. Cai Xuepeng has been President of Chinese Veterinary Association (CVMA) since February 2017. In his professional career, he held a number of prominent leadership roles in government institutions related to control of animal diseases and animal health, including as former Director of Lanzhou Veterinary Research Institute, Director of the Chinese Center for Animal Disease Control and Prevention (CCDC), Director of China Institute of Veterinary Drug Control (IVDC), and Director of Veterinary Drug Evaluation Committee, the Ministry of Agriculture. Dr. Cai received his degree in Veterinary Medicine from Heilongjiang College of Animal Husbandry and Veterinary Medicine, his Master’s Degree in Parasitology from Chinese Academy of Agricultural Sciences, and his PhD in Veterinary Medicine from Nanjing Agricultural University.
才学鹏
中国兽药协会会长
才学鹏先生自2017年2月起担任中国兽药协会会长一职。在他的职业生涯中，他先后担任过与动物疾病防治有关的政府和科研机构要职，包括兰州兽医研究所所长、中国动物疫病预防控制中心主任、中国兽医药品监察所所长和农业部兽药评审中心主任。他本科毕业于黑龙江畜牧兽医学校兽医学专业；在中国农业科学院研究生院兽医寄生虫学与寄生虫病学专业取得硕士学位；在南京农业大学获得了兽医博士学位。
Dr. Isabelle Dieuzy-Labaye
Dr. Isabelle Dieuzy-Labaye is Senior Advisor, Public-Private Partnerships, at the World Organisation for Animal Health (OIE), an intergovernmental organisation with 182 Member Countries, headquartered in Paris.
She has over 20 years of experience in the animal health market and in the life sciences and innovation sectors, working in the US and now in Europe. Prior to her appointment at the OIE in November 2016, Isabelle was the Director, Strategic Alliances, for Europe, Africa and the Middle East at Zoetis, the leading animal health company worldwide. In this role, she started and led multiple open innovation initiatives through collaborations with various partners at the public-private interface, including large academic research entities, government institutions, startup companies, foundations and charities, driving scientific and developmental projects towards outcome and impact.
Isabelle is a board member at Ecole Nationale Vétérinaire d’Alfort and at the Moredun Research Institute in Scotland. She is also a member of the Strategic Committee of Agreenium, the French consortium of agronomical education and research institutes, and of the Technical and Scientific Committee of GALVmed, a UK-based NGO which makes livestock vaccines, medicines and diagnostics accessible and affordable to developing countries. She recently joined the Scientific Council of the Animal Health Department of INRA.
Isabelle holds a DVM from Ecole Nationale Vétérinaire d’Alfort and obtained her MBA at INSEAD.
Clinton Lewis
Clint Lewis is executive vice president and president of International Operations at Zoetis. In this role, he oversees the management of the livestock and companion animal business markets outside the United States.
Mr. Lewis previously served as president, U.S. Operations at Zoetis and in the Pfizer Animal Health organization. He joined Pfizer Animal Health in 2007.
Mr. Lewis joined Pfizer in 1988 as a sales representative in Long Island, N.Y., and has held positions of increasing responsibility in several areas across various commercial operations dedicated to human health prior to joining animal health, including vice president and general manager of Pfizer’s U.S. Anti-Infectives/HIV business unit.
In 2011, Mr. Lewis was elected chairman of the Animal Health Institute (AHI) for the 2011-12 term. A member of AHI since 2007, Mr. Lewis previously served as AHI vice chair for the 2009-2010 term. AHI is the trade association for the animal health industry in the U.S. advocating on various issues important to the industry, including efficient and effective regulatory and approval processes by the U.S. Department of Agriculture (USDA), the Food and Drug Administration (FDA), and the Environmental Protection Agency (EPA).
Mr. Lewis holds a bachelor’s degree in biology from Fairfield University and a Master of Business Administration in marketing from Fairleigh Dickinson University.
Sébastien Huron
Sébastien Huron, 46, DVM, started his career in 1994 in Brazil in the Hoechst-Roussel group where he rapidly rose to become the Marketing director of the animal health division. After Intervet acquired this division (Akzo Nobel group), which was then integrated into the Merck Group, Sébastien Huron pursued his career in 2000 in the United States as Market Development director, and then as director of the Pet division. After rejoining the Virbac group in 2006 as the general manager of the Spanish subsidiary, he then became the director of the European region in 2008, and then head of Global Business Operations in 2013. He has been part of the Virbac executive board since December 2012.
Ruiai Chen
Dr. Ruiai Chen received her Ph.D. in Microbiology from the China Agricultural University. Currently she is a professor and Ph.D. advisor at the College of Veterinary Medicines, South China Agricultural University.
Dr. Chen is President of Guangdong Wens Dahuanong Biotechnology Co., Ltd. (DHN), and Vice-Chairman of the China Veterinary Drug Association (CVDA). She is one of the most influential leaders in the Chinese animal health arena and, as a result, she is entitled to special allowances provided by the Chinese State Council, an honor for outstanding scientists in China. Dr. Chen is a well-known expert in the prevention and control of animal diseases, and vaccine research.
She possesses 41 patents and 22 new veterinary drug certificates. Dr. Chen has received 14 technical awards at the provincial and national levels, such as first prize for the Guangdong Provincial Science and Technology Award and the China Outstanding Patent. Her achievements include the development and industrialization of avian influenza vaccines, PRRS vaccines and coccidiosis vaccines. These vaccines are now making great contributions to disease control in China, Southeast Asia (e.g., Indonesia), and Middle East countries. Dr. Chen is also director of the Enterprise Key Laboratory of MOA for Animal Disease Prevention and Control, Biotechnology and Biological Product R&D. She has contributed greatly to commercialization of technology for animal vaccine and pharmaceutical products.
Dr. Jihong Kim
Dr. Jihong Kim is the chairman of Green Cross Veterinary Products Co., Ltd.. a leading animal health company in South Korea established since 1973. In his role, he is leading the international partnership and globalization initiatives.
Dr. Kim holds MBA from Harvard Business School and PhD from University of California, Berkeley. He was a professor and an associate dean of Korea Development Institute School of Public Policy and Management. He received Official Commendation from Vice Prime Minister, Ministry of Economy and was an Advisory Board Member of Ministry of Finance and Economy, South Korea.
Scott Holmstrom
Alex T. Zhang
More than 20 years' professional experiences in equity investment, management consulting and founder of three successful technology companies
Dr. Hu Hongbin
Occupation:
The president of Beijing E-feed & E-vet (EFEV) Co.Ltd
The Director of Veterinary Drugs Distribution and Service working committee, CVDA
The Compere of International Animal Health Forum, CVDA (China Veterinary Drugs Association)
The Chairman of Beijing Veterinary Drugs Association
The Vice Chairman of China Feed Economy Committee
Education:
1985-1990 Veterinary College, China Agriculture University (Bachelor of Veterinary Science)
2003-2006 Animal Medical College, China Agriculture University (Master of Veterinary Science)
Occupational History:
1990-1991 Veterinarian, Beijing Dongsheng Agriculture & Animal Husbandry Co.Ltd
1992-1994 Sales Consultant/Mainland of China, Veterinary Medicine Division of MSD (Hong Kong) Co.Ltd
1995-1999 Marketing & Sales Director/Great China Region, Animal Health Division of Hoechst GmbH
2000-2001 Sales Manager/China, Intervet Animal health Co.Ltd
2002- President of Beijing E-feed & E-vet (EFEV) Co.Ltd
Dr Xu Bing
Education:
PHD, veterinarian, China Agricultural University
Main Working experience:
2010-present, Chairman, Beijing GoldenVet Biotech Co., Ltd.
2002-2010, Chief Representative (China), Virbac
1999-2002, Marketing manager (China), Schering-Plough Animal health.
1997-1999, Regional Sales Manager, Roche (China) Investment Co., Ltd.
1995-1997, Sales Rep, Conti (Beijing) Feed Additives Ltd.
Emma Davies
Emma Davies advises international clients on M&A and joint ventures in the Asia region, with particular focus on mainland China.
Emma heads up the firm's Corporate practice in mainland China and its Healthcare and Life Sciences Group in Asia.
Emma founded the China competition practice of Clifford Chance and continues to advise clients on the firm's more contentious merger clearances in the market.
Dr. Tony Zi Long Tan
Dr. Tan has over 30 years experience in the field of animal health across a range of animal species. He has had management roles in R&D, regulatory affairs, manufacturing, marketing, sales, and business development. Dr. Tan has extensive international business experience and has worked in the USA, Europe and Asia (particularly in China). Dr. Tan is the founder and Managing Partner of Z-Link Biotech Co. Ltd., a service and support company that helps animal health organizations to achieve their growth and stakeholder value in the emerging market.
Dr. Tan received his veterinary degree from Foshan Veterinary College in China, his Master’s Degree in Animal Science from Alcorn State University, and his Ph.D. in Microbiology from Kansas State University. During his earlier research career, Dr. Tan helped develop several vaccines for cattle, dogs, and poultry. He has published over 50 scientific publications and research reports.
Dr. Tan served Intervet-Schering Plough (now Merck/MSD Animal Health) for over 15 years in different positions, including R&D Group Leader, Project Manager Vaccine Manufacturing, Technical Marketing Manager Aquatic Animals, and Business Unit Director Companion Animals China.
From 2009 to March 2016, Dr. Tan was Group Director of Business Development and Global Alliances for the Asia-Pacific Region of Zoetis (formerly Pfizer Animal Health). He successfully completed several large M&A transactions (total transaction value in excess of US$100 million) and a number of technology licensing deals. These include the first antitrust divesture project in China, the company’s first joint venture project for vaccine manufacturing, and divesture of a pharmaceutical manufacturing plant in Taiwan.
Dr. Tan is an Advisor to the China Global Investment & Trading Alliance (CGITA), an organization that promotes international business between China and other countries.
谭博士在动物保健领域从业超过30年，涉及各种动物品种和岗位部门，包括研发、产品注册、生产、市场、销售以及业务拓展。谭博士拥有丰富的国际工作经验，曾在美国、欧洲和亚洲（特别是中国）国家工作。谭博士是易联生物科技有限公司的创始人。易联生物科技是一家咨询公司帮助动保公司在新兴市场服的发展。
谭博士毕业于佛山兽医专科学校、从阿尔肯州立大学取得了动物科学的硕士学位、从堪萨斯州立大学取得了微生物学的博士学位。在他的研究生涯中，为牛、狗以及家禽类开发了数种疫苗，并且发表了超过50篇科学论文和研究报告。
谭博士在英特威/默沙东动物保健公司工作了超过15年，期间担任了不同职位，包括研发部主管、疫苗制造项目经理、水生动物的技术市场经理以及中国伴侣动物的事业部总监。
从2009年到2016年，谭博士在硕腾（原名辉瑞）担任业务拓展部门和国际联盟亚太地区高级总监。他成功地完成了数项重大企业并购交易（总交易额超过一亿美元）和若干技术转让项目。其中包括中国第一个反垄断剥离项目，辉瑞在中国的第一个合资企业和出售台湾的一家医药制造工厂。
此外，谭博士还是中国际投资和贸易联盟(CGITA)的顾问。CGITA是一个致力于促进中国和其他国家之间国际商务的组织。
Dr. Zhao Yarong
Professor, Yarong ZHAO received Ph.D. in Veterinary Parasitology from China Agricultural University in 1993. With his cutting-edge researches in cryptosporidiosis, he received the First Grade Science & Technology Award from the Chinese Ministry of Agriculture in 1993.
From 1993 to 1998, he worked as National Technical Manager in Bayer Animal Health China. Later then in Fort Dodge Animal Health and Schering-Plough China as Regulatory and Technical Manager.
In 2003, he was appointed as General Manager of the Animal Medicine Research Center of the Dabeinong (DBN) Group, an innovative R&D center which focusing on animal infection disease diagnosis, animal biologic development and technology transfer. He has published over 50 scientific papers. Under his leadership, the Center has obtained Six National New Veterinary Drug Certificates and complete a number of technology transfer to other animal health companies with a total transaction value of approximately 350 million(RMB); Inactivated porcine circovirus type 2 (PCV2) vaccines, won the First Class State Science & Technology Progress Award in 2012.
Mr. Miles Yao
Randolph Seidler
Mark J. Micallef
Nicolas Besse
Kyoon Andrew Kim
Norman Lee
Norman Lee, Ph.D., Professor and founder of Tianjin Ringpu Bio-Technology Co. Ltd., Director of the MOA’s Key Laboratory for Veterinary Drug Innovation, Chairman of the National Veterinary Drug Industry Strategic Alliance for Technology and Innovation, Vice-President of the Chinese Veterinary Association, President of the Tianjin Veterinary Medicine Association, post-graduate advisor at the Tianjin Agricultural University. Dr. Lee has led over 21 national, provincial, and municipal science and technology projects. He was recipient of the second prize of the National Science and Technology Progress Award and twice of the first prize of the Tianjin Science and Technology Progress Award.
In 1998, Dr. Lee established Ringpu(Tianjin)Bio-Pharmacy Co. Ltd. And Ringpu (Baoding) Biological Pharmaceutical Co., Ltd. He also acted as General Manager of both companies.
In 2004, he was in charge of the research project: “Genetically engineering recombinant chicken α- interferon”. The project received the first prize of the Tianjin City Technology Innovation Award.
In 2008, he led a management team to restructure the company and established Tianjin Ringpu Bio-Technology Co. Ltd. He was appointed Acting Chairman of the Board.
On 17th September 2010, Tianjin Ringpu Bio-Technology Co. Ltd. was officially listed on the Shenzhen Stock Exchange and Dr. Lee is Chairman of the Board,
In 2012, Dr. Lee was part of the research team: “Swine and poultry pathogenic bacteria resistance research and its application in development of a safe and effective new veterinary drug”. The project received the second prize of the National Science and Technology Progress Award.
Kristin Bloink
Kristin Bloink manages all internal discovery efforts and all external technology evaluations and subsequent portfolio entries for R&D. She has 26 years of accomplishments in human clinical trials, animal drug discovery and development, translational model development and execution, and human and veterinary clinical medical delivery in the private as well as the military sector. She joined Novartis Animal Health in 2007 and integrated into Elanco Animal Health in 2015.
Dr. Klaus Hellmann
Mark Engel
Carel du Marchie Sarvaas
Carel du Marchie Sarvaas has been working as a senior government affairs and communications advisor in Brussels and Washington DC for 20 years.
He will move to IFAH from EuropaBio, the Association of Biotechnology Industries, where he has been Director for Agricultural Biotechnology for some 4 years. Prior to EuropaBio, Carel worked at international consultancies and think tanks in Brussels and Washington DC, most often serving clients with science-based policy and communications challenges.
Dr. Yuki Ujimasa
Prof. Seong Kyu Song
Dr. Johnny A. Jacobsen
Johnny was appointed to a new role with Argenta in early 2017 as Global Head of Customer Experience and subsequently promoted in 2018 to be the Global Head of Business Development. In this new role, Johnny is leading a team focused on client engagement and relationship management and he also is responsible for the development and execution of the strategic direction of Argenta’s global marketing, branding and communications.
Headline Partner
Associate Partners
Consulting Partner
Event Partner
Media Partners
PARTNER WITH US
Based on your objectives, we can create bespoke packages designed specifically for you. Opportunities predominantly lie in 3 main categories: Thought Leadership, Branding, and Networking.
Interested in a media partnership?
We'd love to hear from you and how we can support one another to connect with the industry. Contact [email protected]
Register
Sending Your Team? Group Discounts Available!
Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates
Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off
If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920
Venue
Sheraton Hong Kong Hotel & Towers, 20 Nathan Road, Kowloon, Hong Kong
Sheraton Hong Kong Hotel & Towers
20 Nathan Road
Kowloon
Hong Kong Special Administrative Region
Hong Kong
Phone: + (852) 2369 1111
Website: click here
Accommodation
We have arranged reduced rates at the conference hotel for event attendees. You can book these via our unique booking link here.
Please note that these discounted accommodation rates expire on October 10, 2018 and are subject to availability.
Global Advisory Board
WHO THEY ARE
Each of our Advisory Board members have been chosen based on numerous recommendations, their deep knowledge and Industry experience and ability to provide a clear vision, not just for their own organizations, but for the industry as a whole.
WHY THEY ARE HERE
Board members guide not just content, but also the underlying mission of the events to drive positive change.
Aaron Schacht
Mr. Jishu Shi
Alan Mackay
Alan has been a private equity investor for more than 25 years in roles including Senior Partner and Global Head of Healthcare at the private equity firm 3i Group plc. He was appointed to the board of 3i plc in 1993 and became CEO of 3i Nordic plc, based in Stockholm, upon the acquisition of Sweden's largest listed private equity company Atle AB in 2001. Alan has served on the boards of a number of healthcare companies, including most recently Phibro Animal Health Corporation which completed a successful initial public offering (IPO) in April 2014. Latterly he has been Managing Partner, CEO, and Chairman of the Investment Committee, of Hermes GPE, an active co-investor in private equity backed healthcare. Alan holds a Bachelor's degree in Law, an MSc in Enterprise and is a graduate of the Advanced Management Programme at INSEAD. He is Chair of the BVCA for 2016 – 2017 and previously chaired its Responsible Investment Advisory Board.
George Gunn
Linda Rhodes
Dr. Rhodes has over 30 years of accomplishments in human and animal drug discovery, development, biomedical research, and clinical veterinary medicine.
Dr. Rhodes was educated at the University of Pennsylvania School of Veterinary Medicine (VMD) and Cornell University (PhD). She has an extensive background in physiology, veterinary medicine, and drug development, and many publications in peer-reviewed journals. Dr. Rhodes practiced clinical veterinary medicine for five years, with experience in both companion and farm animal practice. As a senior research fellow at Merck Research Laboratories for 8 years, she led pre-clinical biology evaluation of several marketed human drugs. She worked for Merial Ltd. as director of large animal development projects, leading project teams developing novel compounds for a variety of indications. In April 2001, she formed AlcheraBio, a consulting, marketing, and contract research firm specializing in developing new drugs for animals, working with biotechnology and animal health companies world-wide. AlcheraBio was acquired in 2008 by Argenta, and Dr. Rhodes served as executive vice president to transition the company when in 2011, she accepted a position as CEO of Aratana Therapeutics, a startup company developing innovative new medicines for dogs and cats. Subsequently, when the company became public she served as its Chief Scientific Officer. During her 5-year tenure, the company achieved FDA approval of three new pet therapeutics: Galliprant, Nocita and Entyce. She is currently retired and an independent consultant. She is a member of the Board of Directors of Zoetis, and serves on the Scientific Advisory Boards of the Alliance for Contraception in Dogs and Cats and the Michelson Found Animals Foundation. She founded Feather in Her Cap, a non-profit that recognizes the achievement of women in the animal health industry. She is the recipient of the Iron Paw Award.
Joachim Hasenmaier
Joachim Hasenmaier, born 1960 in Vaihingen/Enz, Germany, DVM., is Member of the Board of Managing Directors of C.H. Boehringer Sohn AG & Co. KG since October 1, 2012, responsible for the Corporate Board Division Consumer Health Care and Animal Health. His nationality is German.
He received a veterinary medical degree (DVM) in 1986 from Ludwig-Maximilians-University, Munich, where he entered into a microbiological research program until 1989 receiving his Doktor med. vet. (PhD) degree. He completed his education with a Master in Management from Kellogg Business School, Chicago, USA in 1991. Prior to joining BI he worked in various positions for various international companies in Germany, Japan, Mexico and Brazil.
In 2002 he joined Boehringer Ingeheim as Corporate Senior Vice President for Boehringer Ingelheim Animal Health. In 2011 he took over the regional responsibilty for Prescription Medicine in NECAR (UK/Ireland, Nordics, Benelux, Canada, Australia/New Zealand). He held this position until he became Member of the Board of Managing Directors at C.H. Boehringer Sohn AG & Co. KG in October 2012.
Clinton Lewis
Clint Lewis is executive vice president and president of International Operations at Zoetis. In this role, he oversees the management of the livestock and companion animal business markets outside the United States.
Mr. Lewis previously served as president, U.S. Operations at Zoetis and in the Pfizer Animal Health organization. He joined Pfizer Animal Health in 2007.
Mr. Lewis joined Pfizer in 1988 as a sales representative in Long Island, N.Y., and has held positions of increasing responsibility in several areas across various commercial operations dedicated to human health prior to joining animal health, including vice president and general manager of Pfizer’s U.S. Anti-Infectives/HIV business unit.
In 2011, Mr. Lewis was elected chairman of the Animal Health Institute (AHI) for the 2011-12 term. A member of AHI since 2007, Mr. Lewis previously served as AHI vice chair for the 2009-2010 term. AHI is the trade association for the animal health industry in the U.S. advocating on various issues important to the industry, including efficient and effective regulatory and approval processes by the U.S. Department of Agriculture (USDA), the Food and Drug Administration (FDA), and the Environmental Protection Agency (EPA).
Mr. Lewis holds a bachelor’s degree in biology from Fairfield University and a Master of Business Administration in marketing from Fairleigh Dickinson University.
Dirk Ehle
Dr. Dirk Ehle has been a member of the Bayer HealthCare Executive Committee and responsible for the Animal Health Division since May 1, 2012.
Dirk Ehle was born on May 26, 1969, in Cologne, Germany. He studied law at the universities of Freiburg, Aix-en-Provence (France), Wurzburg, and New York (USA).
After three years in law firms, Dirk Ehle started his career at Bayer in 2001 in the Law Department of Bayer HealthCare. In 2006, Ehle transferred to Bayer AG’s Corporate Office where he worked as Executive Assistant to the Chairman of the Board of Management. He was also in charge of Corporate Policy & Advocacy as of 2008. In 2010, Ehle was appointed Senior Bayer Representative for Central Eastern Europe and Bayer HealthCare Representative for Poland.
Dirk Ehle is married with three children.
Dr. James Lloyd
Education
- PhD, Agricultural Economics & Operations Research, Michigan State University, 1989
- DVM, Michigan State University, 1981
- BS, Fisheries & Wildlife, Michigan State University, 1978
Honors and Awards
- LGVMA Leadership Award, 2013
- President’s Honor Roll, Michigan Veterinary Medical Association, 2006, 2007, 2008, 2009, 2011
- Senior Fellow, Outreach and Engagement, Michigan State University, 2005-13
- Certificate of Appreciation, Assoc. of Vet. Practice Management Consultants and Advisors, 2004
- Norden Teacher of the Year Award Finalist, College of Veterinary Medicine, 2003
- Creativity in Teaching Award, Merck Agvet, 1995
- State Team Award, Milk Quality Assurance Program, Michigan State University Extension, 1993
- Commendation (for Extension activity), Michigan Cattlemen’s Association, 1992
- The Honor Society of Phi Kappa Phi, Michigan State University, inducted 1985
- Phi Zeta, Honorary Veterinary Society, Michigan State University, inducted 1981
- Butler Award, voted by peers as “most likely to succeed” in large animal veterinary medicine, 1981
- Honors College, Michigan State University, 1975 to 1977
Interests
Dr. Lloyd was leader of the National Commission on Veterinary Economic Issues working group on Enhancing the Skills, Knowledge, Aptitude, and Attitude of Veterinarians from 2000-2009. He also works as an organization development consultant, emphasizing strategic planning and leadership development with inclusion as a core element.
Sébastien Huron
Sébastien Huron, 46, DVM, started his career in 1994 in Brazil in the Hoechst-Roussel group where he rapidly rose to become the Marketing director of the animal health division. After Intervet acquired this division (Akzo Nobel group), which was then integrated into the Merck Group, Sébastien Huron pursued his career in 2000 in the United States as Market Development director, and then as director of the Pet division. After rejoining the Virbac group in 2006 as the general manager of the Spanish subsidiary, he then became the director of the European region in 2008, and then head of Global Business Operations in 2013. He has been part of the Virbac executive board since December 2012.
Selection Committee
Dr. Tony Zi Long Tan
Dr. Tan has over 30 years experience in the field of animal health across a range of animal species. He has had management roles in R&D, regulatory affairs, manufacturing, marketing, sales, and business development. Dr. Tan has extensive international business experience and has worked in the USA, Europe and Asia (particularly in China). Dr. Tan is the founder and Managing Partner of Z-Link Biotech Co. Ltd., a service and support company that helps animal health organizations to achieve their growth and stakeholder value in the emerging market.
Dr. Tan received his veterinary degree from Foshan Veterinary College in China, his Master’s Degree in Animal Science from Alcorn State University, and his Ph.D. in Microbiology from Kansas State University. During his earlier research career, Dr. Tan helped develop several vaccines for cattle, dogs, and poultry. He has published over 50 scientific publications and research reports.
Dr. Tan served Intervet-Schering Plough (now Merck/MSD Animal Health) for over 15 years in different positions, including R&D Group Leader, Project Manager Vaccine Manufacturing, Technical Marketing Manager Aquatic Animals, and Business Unit Director Companion Animals China.
From 2009 to March 2016, Dr. Tan was Group Director of Business Development and Global Alliances for the Asia-Pacific Region of Zoetis (formerly Pfizer Animal Health). He successfully completed several large M&A transactions (total transaction value in excess of US$100 million) and a number of technology licensing deals. These include the first antitrust divesture project in China, the company’s first joint venture project for vaccine manufacturing, and divesture of a pharmaceutical manufacturing plant in Taiwan.
Dr. Tan is an Advisor to the China Global Investment & Trading Alliance (CGITA), an organization that promotes international business between China and other countries.
谭博士在动物保健领域从业超过30年，涉及各种动物品种和岗位部门，包括研发、产品注册、生产、市场、销售以及业务拓展。谭博士拥有丰富的国际工作经验，曾在美国、欧洲和亚洲（特别是中国）国家工作。谭博士是易联生物科技有限公司的创始人。易联生物科技是一家咨询公司帮助动保公司在新兴市场服的发展。
谭博士毕业于佛山兽医专科学校、从阿尔肯州立大学取得了动物科学的硕士学位、从堪萨斯州立大学取得了微生物学的博士学位。在他的研究生涯中，为牛、狗以及家禽类开发了数种疫苗，并且发表了超过50篇科学论文和研究报告。
谭博士在英特威/默沙东动物保健公司工作了超过15年，期间担任了不同职位，包括研发部主管、疫苗制造项目经理、水生动物的技术市场经理以及中国伴侣动物的事业部总监。
从2009年到2016年，谭博士在硕腾（原名辉瑞）担任业务拓展部门和国际联盟亚太地区高级总监。他成功地完成了数项重大企业并购交易（总交易额超过一亿美元）和若干技术转让项目。其中包括中国第一个反垄断剥离项目，辉瑞在中国的第一个合资企业和出售台湾的一家医药制造工厂。
此外，谭博士还是中国际投资和贸易联盟(CGITA)的顾问。CGITA是一个致力于促进中国和其他国家之间国际商务的组织。
Dr. Hu Hongbin
Occupation:
The president of Beijing E-feed & E-vet (EFEV) Co.Ltd
The Director of Veterinary Drugs Distribution and Service working committee, CVDA
The Compere of International Animal Health Forum, CVDA (China Veterinary Drugs Association)
The Chairman of Beijing Veterinary Drugs Association
The Vice Chairman of China Feed Economy Committee
Education:
1985-1990 Veterinary College, China Agriculture University (Bachelor of Veterinary Science)
2003-2006 Animal Medical College, China Agriculture University (Master of Veterinary Science)
Occupational History:
1990-1991 Veterinarian, Beijing Dongsheng Agriculture & Animal Husbandry Co.Ltd
1992-1994 Sales Consultant/Mainland of China, Veterinary Medicine Division of MSD (Hong Kong) Co.Ltd
1995-1999 Marketing & Sales Director/Great China Region, Animal Health Division of Hoechst GmbH
2000-2001 Sales Manager/China, Intervet Animal health Co.Ltd
2002- President of Beijing E-feed & E-vet (EFEV) Co.Ltd
Mr. Miles Yao
Mark Heffernan
Prior to joining Stonehaven Incubate, Dr Heffernan was the founding CEO and director at Nexvet Biopharma plc, a company pioneering the development of monoclonal antibodies in animal health. Since co-founding Nexvet in 2010, he raised more than US$80 million in capital, including the company’s NASDAQ public listing in 2015. Nexvet Biopharma was acquired by the world’s largest animal health company, Zoetis, in 2017.
Prior to Nexvet, he was also co-founder of an Irish biotechnology company, Opsona Therapeutics, focused on therapeutics for human inflammatory diseases where he raised US$50 million to commercialise research from Trinity College Dublin. Through his career, he has worked in research and business development in the USA, Asia Pacific and Europe.
About Kisaco Research
Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.
Meet industry peers that will help build a career-changing network for life.
Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.
Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.
Invest both in your company growth and your own personal development by signing up to one of our events and get started.